BioSpace News Archive

The oxygen cylinders and concentrators market is projected to record tremendous growth on account of rising elderly population base that is mostly prone to chronic respiratory diseases like asthma, pulmonary, and COPD.

The pacemaker market is anticipated to log fast-paced growth on account of rising prevalence of heart- related disorders like heart blockages, bradycardia, and tachycardia. Increasing public awareness on the options available for the treatment of abnormal heart rhythms or heart arrhythmia disorder could massively benefit its business outlook.

Parenteral nutrition is concerned with the maintenance of important nutrition of the body for those who cannot eat or absorb enough food through mouth or tube feeding.

The pet cancer therapeutics market is likely to witness sizable revenue growth on account of rising consumer spending on pet healthcare.

The Board of Directors of McKesson Corporation yesterday declared a regular dividend of 42 cents per share of common stock.

Growing skin problems and a higher awareness regarding new treatments will fuel photorejuvenation devices market share over the forecast period.

Pharmacy Launched During Pandemic Through Joint Venture Funding Drives New Source of Revenue For Hospital And Expands Services To Patients

The influx of the latest technologies and the spike in the number of birth rates worldwide will influence point of care ultrasound market trends over the coming years.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal second quarter 2021 financial results after the market closes on Thursday, February 11,

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. Bellicum worked diligently with t